AFMD Affimed N.V.

Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019

Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019



 

Heidelberg, Germany, July 31, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it will host a conference call on Wednesday, August 7, 2019 at 8:30 a.m. ET to discuss its second quarter 2019 financial results and recent corporate developments.

The conference call will be available via phone and webcast. To access the call, please dial for U.S. callers, or +44 (0) 203 0095710 for international callers, and reference conference ID 9396039 approximately 15 minutes prior to the call.

An audio webcast of the conference call can be accessed in the “Webcasts” section on the “Investors” page of the Affimed website at . A replay of the webcast will be available on Affimed’s website shortly after the conclusion of the call and will be archived for 30 days following the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The Company is developing single and combination therapies to treat hematologic and solid tumors. For more information, please visit .

Affimed Investor Contact:

Gregory Gin, Head of Investor Relations

E-Mail:

Affimed Media Contact:

Anca Alexandru, Head of Communications, EU IR

E-Mail:

EN
31/07/2019

Underlying

AFMDAffimed N.V.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Affimed N.V.

 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Announces Receipt of Nasdaq Delisting Notice

Affimed Announces Receipt of Nasdaq Delisting Notice MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 No...

May 14, 2025 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Announces Filing for the Opening of Insolvency Proceedings

Affimed Announces Filing for the Opening of Insolvency Proceedings MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the “Company”) has been engaged in discussions with potential investors and partners with respect to potential strategic transactions to raise additional capita...

May 13, 2025 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Shows Higher Exposure of AFM24 is Associated with Significantl...

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safetyThese findings will be incorporated in future AFM24 trials to further improve e...

April 29, 2025 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Announces Acceptance of Three Abstracts for Presentation at th...

Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE®) acimtamig in combination with AlloNK® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinica...

April 23, 2025 1 EN
 PRESS RELEASE
Free
AFMD AFFIMED N.V.

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimu...

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed be...

April 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch